AU2024202561B1 — Treatment of Hemangioma
Assigned to Gillies Mcindoe Research Institute · Expires 2025-03-06 · 1y expired
What this patent protects
The invention relates to a medicament or method for topically treating hemangioma, comprising, or administering, Propranolol and Fosinopril in a molar ratio of 2 to 0.9 - 1.3 respectively. The invention also relates to the use of Propranolol and Fosinopril in the manufacture o…
USPTO Abstract
The invention relates to a medicament or method for topically treating hemangioma, comprising, or administering, Propranolol and Fosinopril in a molar ratio of 2 to 0.9 - 1.3 respectively. The invention also relates to the use of Propranolol and Fosinopril in the manufacture of a medicament for topical administration to a human patient for treating hemangioma, where the Propranolol and Fosinopril are in a molar ratio of 2 to 0.9 - 1.3.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.